BioReview

Biotechnology

The $12 Billion Question: What Novartis's DM1 Failure Reveals About the Limits of Acquisition-Driven Drug Development

Novartis's $12 billion acquisition of Avidity Biosciences and the subsequent failure of del-desiran in Phase 3 trials reveals critical lessons about the limits of acquisition-driven drug development in rare disease.

Biotechnology

The Long Road to a First: What uniQure's Huntington's Disease Gene Therapy Filing Really Means

uniQure has filed the first-ever gene therapy application for Huntington's disease. The science is compelling, the regulatory backstory is dramatic, and the stakes for 30,000 Americans and 200,000 at-risk individuals could not be higher.

Pharmaceuticals

Reading the Blood: What Etcamah's Approval Means for Breast Cancer and the Liquid Biopsy Era

AstraZeneca's Etcamah became the first FDA-approved cancer therapy triggered by a blood test detecting resistance before imaging shows progression. The approval rewrites how oncologists think about treatment switching in HR-positive breast cancer.

Biotechnology

A Name for the Nameless: What Zanvastro's Approval Means for Alexander Disease and RNA Medicine

The FDA's approval of Zanvastro marks the first treatment ever approved for Alexander disease, signaling a broader shift in how RNA-targeted therapies can address ultra-rare neurological conditions.

Biotechnology

Medicine Made to Order: What ARPA-H's $125 Million RNA Manufacturing Bet Really Means

ARPA-H's $125 million GIVE program aims to revolutionize RNA medicine manufacturing through distributed, automated platforms that can produce personalized therapies on demand near patients.

Pharmaceuticals

The Second Wave: Why GSK's mRNA Flu Vaccine Push Could Reshape a Market Moderna Just Opened

GSK is advancing an mRNA flu vaccine that targets both hemagglutinin and neuraminidase into Phase 3, a more ambitious dual-antigen approach than Moderna's recently approved mFlusiva. Here is what the science means and why it matters.

Biotechnology

When the Promise Meets the Risk: What the Novartis and BMS Autoimmune CAR-T Halts Really Mean

Novartis and Bristol Myers Squibb paused their autoimmune CAR-T programs on the same day, forcing the field to reckon with safety challenges that may be inherent to translating oncology science into autoimmune disease.

Pharmaceuticals

Thirty Years in the Making: What the FDA's BESREMi Approval Means for Essential Thrombocythemia

The FDA's approval of BESREMi marks the first new therapy for essential thrombocythemia in nearly 30 years, signaling a shift toward disease-modifying treatments that target the molecular drivers of this rare blood cancer.

Pharmaceuticals

The Last Frontier in Cardiology: Why the Lp(a) Drug Race Could Rewrite Heart Disease Prevention

Novartis, Amgen, and Eli Lilly are racing to address Lp(a), a genetic cardiovascular risk factor affecting 1 in 5 people with no approved treatment. The first pivotal outcomes data could arrive within weeks.

Biotechnology

The Undruggable Made Druggable: What Rasonque's FDA Approval Means for Pancreatic Cancer and the RAS Era

The FDA's approval of Rasonque marks a watershed moment in oncology—the first therapy to directly target RAS, ending three decades of failed attempts to drug one of cancer's most intractable targets.

Pharmaceuticals

Fixing the Wiring: What Takeda's Orzeyful Approval Means for Narcolepsy and the Orexin Era

Takeda's FDA approval of Orzeyful marks a paradigm shift in narcolepsy treatment—the first medicine to directly target orexin deficiency rather than manage symptoms.

Biotechnology

Beyond GLP-1: Roche's $2.3B Bet on Muscle-Sparing Obesity Science

Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.